Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer
August 19, 2024 08:45 ET
|
Sonnet BioTherapeutics Holdings, Inc.
Preclinical data has demonstrated the potential of SON-1210, the first albumin-binding bifunctional IL-12/IL-15 fusion protein, for solid tumor immunotherapy An Innovative Immuno Oncology...
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
August 14, 2024 08:35 ET
|
Sonnet BioTherapeutics Holdings, Inc.
Ongoing progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Partnership efforts to support initiation of a Phase 2 clinical...
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
July 24, 2024 08:30 ET
|
Sonnet BioTherapeutics Holdings, Inc.
Data indicates that SON-080 was well-tolerated at both doses, with no evidence of a pro-inflammatory cytokine responsePain and quality of life survey results suggest the potential for rapid...
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
June 20, 2024 08:30 ET
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, N.J., June 20, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic...
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
June 13, 2024 08:00 ET
|
Sonnet BioTherapeutics Holdings, Inc.
Sonnet discovered and characterized a modified version of Interleukin-18 (IL-18Binding Protein Resistant or IL-18BPR) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with...
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
May 28, 2024 08:00 ET
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic...
Sonnet BioTherapeutics Holdings Announces Merger Closing
April 01, 2020 17:53 ET
|
Sonnet BioTherapeutics Holdings, Inc.
- Trading under “SONN” on the Nasdaq Capital Market to begin April 2, 2020- Closed $19 million financing PRINCEON, N.J., April 01, 2020 (GLOBE NEWSWIRE) -- Sonnet BioTherapuetics Holdings, Inc.,...
Chanticleer Holdings Announces 1-for-26 Reverse Stock Split
March 31, 2020 16:06 ET
|
Chanticleer Holdings, Inc.
Nasdaq approves continued listing of Sonnet BioTherapeutics following closing of mergerMerger transaction expected to close on April 1, 2020Trading under “SONN” expected to begin April 2, 2020 ...
Chanticleer Holdings Announces 1:1 Distribution Ratio for Spin-Off and Provides Corporate Update
March 24, 2020 17:38 ET
|
Chanticleer Holdings, Inc.
CHARLOTTE, N.C., March 24, 2020 (GLOBE NEWSWIRE) -- Chanticleer Holdings, Inc. (Nasdaq: BURG) (the “Company” or “Chanticleer”), owner, operator and franchisor of multiple nationally-recognized...
Chanticleer Holdings Announces Results of Shareholder Vote
March 19, 2020 08:30 ET
|
Chanticleer Holdings, Inc.
CHARLOTTE, N.C., March 19, 2020 (GLOBE NEWSWIRE) -- Chanticleer Holdings, Inc. (NASDAQ:BURG) (“Chanticleer” or the “Company”), owner, operator, and franchisor of multiple nationally recognized...